| Good practices in model‐informed drug discovery and development: practice, application, and documentation EFPIA MID3 Workgroup, SF Marshall, R Burghaus, V Cosson, ... CPT: pharmacometrics & systems pharmacology 5 (3), 93-122, 2016 | 257 | 2016 |
| Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache HO Høivik, BE Laurijssens, LO Harnisch, CK Twomey, RM Dixon, ... Cephalalgia 30 (12), 1458-1467, 2010 | 90 | 2010 |
| Drug and disease model resources: a consortium to create standards and tools to enhance model‐based drug development L Harnisch, I Matthews, J Chard, MO Karlsson CPT: Pharmacometrics & Systems Pharmacology 2 (3), 1-3, 2013 | 47 | 2013 |
| Modeling and simulation as a tool to bridge efficacy and safety data in special populations L Harnisch, T Shepard, G Pons, O Della Pasqua CPT: pharmacometrics & systems pharmacology 2 (2), 1-4, 2013 | 45 | 2013 |
| Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ... CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015 | 41 | 2015 |
| Population kinetics of gentamicin in neonates W Weber, G Kewitz, KL Rost, M Looby, M Nitz, L Harnisch European Journal of Clinical Pharmacology 44, S23-S25, 1993 | 40 | 1993 |
| Elucidation of factor VIII activity pharmacokinetics: a pooled population analysis in patients with hemophilia A treated with moroctocog alfa JA Abrantes, EI Nielsen, J Korth‐Bradley, L Harnisch, S Jönsson Clinical Pharmacology & Therapeutics 102 (6), 977-988, 2017 | 28 | 2017 |
| Advancing clinical trial design in pulmonary hypertension AP Grieve, SC Chow, J Curram, S Dawe, LO Harnisch, NR Henig, ... Pulmonary circulation 3 (1), 217-225, 2013 | 25 | 2013 |
| Application of quantitative pharmacology approaches in bridging pharmacokinetics and pharmacodynamics of domagrozumab from adult healthy subjects to pediatric patients with … I Bhattacharya, Z Manukyan, P Chan, A Heatherington, L Harnisch The Journal of Clinical Pharmacology 58 (3), 314-326, 2018 | 21 | 2018 |
| Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine K Hoye, BE Laurijssens, LO Harnisch, CK Twomey, RM Dixon, A Kirkham Cephalalgia 29 (1), 132, 2009 | 21 | 2009 |
| Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension CD Vizza, BKS Sastry, Z Safdar, L Harnisch, X Gao, M Zhang, M Lamba, ... BMC pulmonary medicine 17, 1-12, 2017 | 19 | 2017 |
| Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy DJ Conrado, J Larkindale, A Berg, M Hill, J Burton, KR Abrams, ... Journal of pharmacokinetics and pharmacodynamics 46, 441-455, 2019 | 17 | 2019 |
| Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery W Weber, L Harnisch, A Jessel Clinical Pharmacology & Therapeutics 71 (6), 457-467, 2002 | 17 | 2002 |
| Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new DMARD in the treatment of rheumatoid arthritis. W Weber, L Harnisch ARTHRITIS AND RHEUMATISM 40 (9), 731-731, 1997 | 14 | 1997 |
| Model description language (MDL): a standard for modeling and simulation MK Smith, SL Moodie, R Bizzotto, E Blaudez, E Borella, L Carrara, ... CPT: pharmacometrics & systems pharmacology 6 (10), 647, 2017 | 12 | 2017 |
| Making every subject count: a case study of drug development path for medication in a pediatric rare disease I Bhattacharya, Z Manukyan, P Chan, L Harnisch, A Heatherington Clinical Pharmacology & Therapeutics 100 (4), 330-332, 2016 | 11 | 2016 |
| Modeling of survival and frequency of cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy treated with tafamidis C Vong, M Boucher, S Riley, LO Harnisch American Journal of Cardiovascular Drugs 21, 535-543, 2021 | 10 | 2021 |
| The population approach: measuring and managing variability in response, concentration and dose W Weber, L Harnisch COST B1 medicine: European cooperation in the field of scientific and …, 1997 | 8 | 1997 |
| The effect of activated charcoal and cholestyramine on the pharmacokinetics of leflunomide HJ Roethig, J Collins, L Harnisch, C Rokitta, W Weber Clinical Pharmacology & Therapeutics 59 (2), 204-204, 1996 | 8 | 1996 |
| Thoughtflow: standards and tools for provenance capture and workflow definition to support model‐informed drug discovery and development JJ Wilkins, PLS Chan, J Chard, G Smith, MK Smith, M Beer, A Dunn, ... CPT: Pharmacometrics & Systems Pharmacology 6 (5), 285-292, 2017 | 6 | 2017 |
